Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies
OBJECTIVES: I. Determine the 1-year survival rate of patients with hematologic malignancies
after treatment with HLA-matched allogeneic bone marrow transplantation after high-dose
OUTLINE: Patients receive oral busulfan four times a day on days -8 to -5, cyclophosphamide
IV over 1 hour on days -4 to -1, and methylprednisolone IV over 1 hour every 12 hours on
days -2 to 0. CD34+ stem cell augmented donor bone marrow is infused on day 0.
Methylprednisolone is administered IV over 1 hour on days 5-16, and then tapered. Patients
are followed every 6 months for 1 year and then annually thereafter.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.
Primary Purpose: Treatment
Paul V. O'Donnell, MD, PhD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Johns Hopkins Oncology Center||Baltimore, Maryland 21287|
|Center for Cancer Treatment and Research||Columbia, South Carolina 29203|